RYTM Q2 2022 Earnings — Rhythm Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RYTMRhythm Pharmaceuticals, Inc.

$6B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M+3208.8% YoY

Gross Profit

$9M95.8% margin

Operating Income

-$45M-497.4% margin

Net Income

-$45M-496.4% margin

EPS (Diluted)

$-0.89

QoQ Revenue Growth

+505.2%

Cash Flow

Operating Cash Flow

-$39M

Free Cash Flow

-$43M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$278M

Total Liabilities

$82M

Stockholders' Equity

$196M

Cash & Equivalents

$113M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$274,000	+3208.8%
Gross Profit	$9M	$137,000	+6241.6%
Operating Income	-$45M	-$40M	-11.5%
Net Income	-$45M	-$35M	-27.2%

Revenue Segments

License revenue

$7M74%

Product revenue

$2M26%